This week’s news stories remind us that the psychedelic renaissance is a truly global phenomenon. In Japan, pharmaceutical giant Otsuka has struck a deal with Atai Life Sciences’ Perception Neuroscience to commercialise the latter’s R-ketamine (PCN-101) for mood disorders. In Australia, the federal government has earmarked $15m in grants to support psychedelic research, becoming one of only a…


Previous articleNuminus Announces Closing of $40-Million Bought Deal Financing
Next articleMindMed Announces Inclusion in FTSE Russell Indexes